

For Health Professionals

Meningococcal Vaccines for Adolescents & Young Adults: Routine Risk¹

Routine MenACWY^{2,3} for 11-18 years

2 Doses

MenACWY
MenQuadfi[®] or
Menveo[®]

Ages 11 or 12 years

8 weeks min.

MenACWY
MenQuadfi[®] or
Menveo[®]

Age 16 years

Catch-up⁴:

- Ages 13-15 years: 1 dose now and booster at age 16-18 years.
- Ages 16-18 years: 1 dose

Shared Clinical Decision-Making MenB² for 16-23 years

2 Doses

Preferred age is 16-18 years

MenB
Bexsero[®]

At least 1 month

MenB
Bexsero[®]

MenB
Trumenba[®]

At least 6 months

MenB⁵
Trumenba[®]

- If dose 2 is administered earlier than 6 months, administer 3rd dose at least 4 months after dose 2.

Use the same brand of MenB Vaccine for each dose in the series.

More Information: https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm#T3_down

Notes:

1. For HIGH-RISK POPULATIONS (increased exposure to meningococcal disease, HIV infection, complement deficiencies or asplenia), see recommendations at [EZIZ.org/assets/docs/IMM-1218.pdf](https://www.eziz.org/assets/docs/IMM-1218.pdf)
2. MenACWY and MenB vaccines each protect against different serogroups. They may be given at the same visit.
3. MenACWY (MCV4) vaccines protect against serogroups A, C, W-135, and Y.
4. One dose of MenACWY is also recommended for previously unvaccinated or incompletely vaccinated first-year college students living in residence halls and military recruits and may be administered to persons aged 19-21 yrs. who have not received a dose after their 16th birthday.
5. A two-dose series is recommended for persons who are not at increased risk for meningococcal disease. A three-dose (0, 1-2, and 6 months) series is recommended for persons at increased risk, including during outbreaks of serogroup B disease: see [EZIZ.org/assets/docs/IMM-1218.pdf](https://www.eziz.org/assets/docs/IMM-1218.pdf).



California Department of Public Health,
Immunization Branch
This publication was supported by Grant
Number H23/CCH922507 from the Centers
for Disease Control and Prevention (CDC)

EZIZ.org IMM-1217 (10/22)